The Conversation (0)
Stem Cell Therapeutics Corp. (TSXV:SSS), a life sciences company that focuses on stem cell technologies, announced the execution of a Letter of Agreement with Toronto-based Trillium Therapeutics Inc., under which, the latter will be merged into Stem Cell Therapeutics Corp by means of a plan of arrangement with a newly-developed SCT subsidiary.
Stem Cell Therapeutics Corp. a life sciences company that focuses on stem cell technologies, announced the execution of a Letter of Agreement with Toronto-based Trillium Therapeutics Inc., under which, the latter will be merged into Stem Cell Therapeutics Corp by means of a plan of arrangement with a newly-developed SCT subsidiary.
As quoted in the press release:
The proposed merger of Trillium and SCT would create Canada’s only public company advancing cancer stem cell technologies,” said David Allan, the Executive Chairman of SCT. “With a combined pipeline containing both TTI-621 and the Tigecycline small-molecule program, which SCT recently optioned from the University Health Network, the resulting entity will be well positioned as a global contender in the cancer stem cell field.
Click here to read the full Stem Cell Therapeutics Corp. press release.
